Family Medicine · Year 3 · from Family Medicine
Case 2: Cardiovascular Risk Assessment and Statin Decision
Patient Demographics
- Age: 48 years old
- Sex: Male
- Occupation: Software engineer
Chief Complaint
"My cholesterol came back high on a work screening. Do I need to be on medication?"
History of Present Illness
Mr. David Park is a 48-year-old man who had a biometric screening at work that revealed total cholesterol of 248 mg/dL. He is concerned and wants to know if he needs medication. He has no chest pain, shortness of breath, or other cardiac symptoms. He exercises occasionally (walks 1-2 times weekly) and tries to "eat healthy" but admits to frequent fast food meals due to work demands.
Past Medical History
- No known chronic conditions
- No prior cardiac events
- No diabetes
Family History
- Father: MI at age 58, currently alive with CAD
- Mother: Hyperlipidemia, on statin
- No family history of diabetes
Social History
- Never smoker
- Alcohol: 2-3 beers weekly
- Married with two children
- High-stress job with long hours
- Sedentary work
Physical Examination
- Vital Signs: BP 128/84, HR 72, BMI 27
- General: Well-appearing, mildly overweight
- Cardiovascular: Regular rate and rhythm, no murmurs
- Peripheral pulses: Normal
- No xanthomas or xanthelasma
Laboratory Results (fasting)
- Total cholesterol: 252 mg/dL
- LDL cholesterol: 168 mg/dL
- HDL cholesterol: 42 mg/dL
- Triglycerides: 210 mg/dL
- Fasting glucose: 102 mg/dL (impaired fasting glucose)
- HbA1c: 5.9%
Cardiovascular Risk Calculation
Using ASCVD Risk Calculator:
- Age: 48
- Sex: Male
- Race: Asian
- Total cholesterol: 252
- HDL: 42
- Systolic BP: 128 (untreated)
- Diabetes: No
- Smoker: No
10-year ASCVD Risk: 6.8% (borderline risk: 5-7.5%)
Risk-enhancing factors present:
- Family history of premature ASCVD (father MI at 58)
- Metabolic syndrome features (low HDL, elevated TG, impaired fasting glucose)
- LDL > 160 mg/dL
Assessment
- Hyperlipidemia with LDL 168 mg/dL
- Borderline ASCVD risk (6.8%) with multiple risk-enhancing factors
- Prediabetes (IFG and HbA1c 5.9%)
- Metabolic syndrome - meets criteria
Management Plan
Shared Decision-Making Discussion: Explained to patient:
- His 10-year risk of heart attack or stroke is approximately 7%
- Risk-enhancing factors (family history, metabolic syndrome) increase his true risk
- Options: lifestyle changes alone vs. lifestyle + statin therapy
- Statin benefits: Would reduce his risk by approximately 25-30%
- Statin risks: Muscle aches (5-10%), rare liver issues, small diabetes risk increase
Patient Decision: After discussion, patient elects to try intensive lifestyle modification for 3-6 months before starting medication.
Lifestyle Prescription:
- Diet: Mediterranean or DASH pattern, limit saturated fat <7% calories, increase fiber
- Exercise: Goal 150 min/week moderate intensity; start with 30 min walking 5x/week
- Weight: Target 5-7% weight loss (goal weight: 175 lbs from current 185 lbs)
- Referral to registered dietitian
If Statin Indicated (follow-up):
- Would recommend moderate-intensity statin (atorvastatin 20mg or rosuvastatin 10mg)
- Given risk-enhancing factors, may still recommend statin at follow-up
Prediabetes Management:
- Discussed progression risk
- Intensive lifestyle intervention (same as above)
- Consider Diabetes Prevention Program referral
Follow-Up
- Repeat fasting lipid panel in 3 months
- Monitor weight and lifestyle adherence
- Reassess statin decision at 3-month visit
- Annual diabetes screening
Teaching Points
- Risk calculation: The ASCVD risk calculator is essential for guiding statin decisions in primary prevention. Raw cholesterol numbers alone are insufficient.
- Risk-enhancing factors: Borderline risk patients with risk-enhancing factors (family history, metabolic syndrome, LDL > 160) benefit from more intensive discussions about statin therapy.
- Shared decision-making: Statin therapy for primary prevention is a preference-sensitive decision. Some patients prefer medication; others want to try lifestyle first.
- Lifestyle as foundation: Therapeutic lifestyle change is the foundation of cardiovascular prevention regardless of medication decisions.